SUMMARY Twenty nine patients with motor neuron disease receiving a thyrotropin releasing hormone analogue showed acute 25-30% increase in mean corrected fibre density and mean macro EMG median amplitude and area in brachial biceps muscle. The data are consistent with a direct or indirect action of the drug on anterior horn cells. 
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There is neurophysiological evidence to suggest that thyrotropin releasing hormone (TRH) and analogues have a pharmacological action on anterior horn cells in the frog,' 2 toad,3 rat4- 7 and cat.8 Acute clinical trials of TRH9 and of RX77368, a stabilised TRH analogue,'0 in patients with motor neuron disease have documented temporary increase in fasciculations, decrease in spasticity, improvement in bulbar function parameters and change in muscle force, but not in fatigability. F and H wave studies suggest an action of native TRH on human spinal interneurons." 12 RX77368 contains a 3,3 dimethyl substituted prolineamide residue'3 14 which impairs degradation by peptidases.'5 It is 14-200 times more potent than TRH on a molar basis on various tests of neuropharmacological activity yet its endocrine effect is of the same magnitude.'6 "7 Its much greater neuropharmacological potency possibly relates to slow enzymatic degradation in nervous tissue.'5 18 19 In humans, half-life is 158 minutes in homogenates of brain and 1080 minutes in plasma, compared with 18 minutes and 5-33 minutes respectively for TRH.15 16 We have studied, in motor neuron disease patients, the acute effects of RX77368 on electrophysiological parameters that index (1) motor unit microfunction (fibre density = FD), and macro function (macro EMG = MAC, compound muscle action potential = MAP), (2) fastest conducting motor fibres (maximal motor conduction. velocity = MCV, distal motor latency = DML) (3) Neuro-muscular junction (repetitive stimulation) (4) fast conducting sensory fibres (median nerve sensory action potential = SAP).
Material and methods
Twenty nine patients with motor neuron disease participated in a double blind, randomised crossover trial of Lpyroglutamyl L-hystidyl L-3,3 dimethyl prolineamide (RX77368) 0 
Results
There was no significant difference in mean FD in trial patients and controls (fig 2) . Mean MAC amplitude and area were also not significantly different in these two groups (mean difference for amplitude was 105-9gV, SD126 and for area 509 9gV x ms,
SD553-3).
There was a statistically significant increase in mean FD between saline and drug infusions, but not between two recordings in controls (fig 2) . The mean increase of 0-3 represents 30% of the corrected fibre density (FD-1), mean value of 105. In trial patients the increase in FD was similar for the subsets with FD below 2-0 and 2-0 or above (mean increase 0-28, SE 0-06 and 0-31 SE, 0 1 1 respectively). The same subsets in controls show no significant difference between two successive recordings of FD.
In eight trial patients recordings of FD during saline and drug infusions were expressed as change from baseline (fig 3) . A significant difference between drug and saline was found.
There was a statistically significant increase in mean median MAC amplitude (26%) and area (28%) between drug and saline infusions, but not between two control recordings (fig 4) calculated from the saline value in trial patients and from the mean of the two values in control patients. The differences between the two pairs also held when the percentage change for the two control values was calculated from the first or second of the two. There was no significant change in the mean percentage of individual MAC potentials with amplitude above the upper limit of normal for age between saline and drug infusion (310% SE 7-0 and 38 5% SE 78 respectively, n = 19). The correlation coefficient r between percentage change in median MAC area and amplitude from saline to drug in each trial patient and from first to second recording in each control patient was 0-85 (n = 33; p < 0 001). Using log transformations there was also a highly significant correlation between the 20-22 pairs of MAC amplitude and area from which MCV (n = 16) and DML (n = 17) at 2 1 of abductor digiti minimi at 1 and 2 hou decrement of MAP of abductor digiti l repetitive stimulation at 3 Hz at 1 at (n = 12), median SAP amplitude, laten and latency to peak at 2 hours (n = 10).
Discussion median MAC amplitude and area of biceps during IV infusion of a TRH analogue has been found. The absence of change in maximal motor conduction (MCV, DML) is against an effect of the drug on fastest conducting motor fibres in the nerve trunk and distally. The lack of fatigability both clinically"0 and on repetitive stimulation argues against a major effect on the neuromuscular junction.
It is unlikely that the increase in the mean median MAC amplitude and area with drug is artefactual. The examiner, recording equipment and electrode were kept constant. Averaging was started when monitoring only the single fibre signal. (39) (20) 
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